文献速递免疫规划传染病防控与疫情报告

季节性疫苗中包含两种乙型流感病毒谱系的依据:关于免疫原性与对照现场试验的Meta回归研究

Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials.
PubMed 文献 · Vaccine · 2017-06-24

该研究通过系统检索免疫原性研究和伞形检索随机对照试验及检测阴性病例对照试验,评估乙型流感病毒谱系不匹配对抗体诱导和疫苗效果的影响。结果显示,无既往免疫时谱系不匹配使抗体预测疫苗效果从69%降至-4%,随既往暴露增加不匹配影响减小;匹配季节平均现场疫苗效果67%,不匹配季节35%。

要点

  • 无既往免疫时,匹配谱系的抗体预测疫苗效果平均为69%,不匹配为-4%。
  • 随接种前血清阳性率增加,不匹配影响下降至2%。
  • 匹配季节现场疫苗效果平均67%,不匹配季节35%,不匹配影响随既往暴露增加而减小。

核心结论

  • 血清学和现场试验表明,乙型流感病毒谱系不匹配的影响与季节前免疫负相关。
  • 四价流感疫苗相对于三价流感疫苗的增益最有益于尚未暴露于乙型流感的婴幼儿和儿童。

研究设计与样本

  • 对评估四价流感疫苗相对于三价流感疫苗抗体优越性的免疫原性研究进行系统文献检索,13篇相关文章描述了2007年至2013年的31项试验。
  • 对三价流感疫苗的随机对照试验和检测阴性病例对照试验进行伞形文献检索,68篇符合条件的临床文章描述了1965年至2012年的110项季节试验。

主要发现

  • 无特定接种前免疫时,匹配谱系的抗体预测疫苗效果平均为69%,谱系不匹配为-4%。
  • 随接种前血清阳性率增加,不匹配影响下降至2%。
  • 无接种前抗体水平时,以既往暴露于乙型流感的概率作为季节前免疫指标;既往暴露概率为0%时,匹配季节现场疫苗效果平均67%,不匹配季节35%,表明不匹配对现场疫苗效果有中等但显著的影响。
  • 随既往暴露概率增加,不匹配影响下降至3%。

关键数值与推荐

  • 无特定接种前免疫时,匹配谱系的抗体预测疫苗效果平均69%,谱系不匹配为-4%。
  • 随接种前血清阳性率增加,不匹配影响下降至2%。
  • 既往暴露概率为0%时,匹配季节现场疫苗效果平均67%,不匹配季节35%。
  • 随既往暴露概率增加,不匹配影响下降至3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B lineage mismatch prompted introduction of quadri-valent influenza vaccines (QIV) with two influenza B viruses representing distinct antigenic lineages. To explore the impact on antibody induction and vaccine effectiveness predicted from antibody (VEab), we performed a systematic literature search on immunogenicity studies conducted to assess antibody superiority of QIV over trivalent influenza vaccine (TIV). Thirteen relevant articles described 31 trials from 2007 and 2013. Log-transformed GMT trial estimates and their variances were converted to clinical protection rates predicted from antibody (PRab). VEab estimates were calculated from pre- and post-vaccination PRab. Without specific pre-vaccination immunity, average VEab was 69% for match, and -4% for lineage mismatch. With increasing pre-vaccination seropositivity, mismatch impact declined to 2%. We also performed an umbrella literature search for randomised controlled trials and test-negative case-control trials with TIV, and estimated vaccine effectiveness against laboratory-confirmed influenza B (VEf). Sixty-eight eligible clinical articles described 110 season-trials from 1965 to 2012, covering seasons with B lineage match (n=52), lineage drift (n=15) and lineage mismatch (n=43). With no pre-vaccination antibody levels determined, we used chance of previous exposure to influenza B (Ppe) as pre-seasonal immunity measure. When Ppe was 0%, average VEf for matched seasons was 67%, and for mismatched seasons 35%, indicating a moderate, yet significant mismatch impact on VEf. With increasing Ppe, mismatch impact declined to 3%. Thus serological and field trials indicate that B lineage mismatch impact is negatively related to pre-seasonal immunity and that the gain of QIV over TIV most benefits infants and children not yet exposed to influenza B.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Beyer WEP, Palache AM, Boulfich M, et al. Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials. Vaccine. 2017. PMID: 28655451. doi:10.1016/j.vaccine.2017.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。